This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Anthera Pharmaceuticals Inc (ANTH)

: Health Care

Company Cash Flow
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Cash Flow From Operating Activities
Net Income (Loss) -35.22M -29.60M -30.86M -59.40M
Operating Gains/Losses 0.00 0.00 12.00K 46.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -326.00K 0.00 0.00 0.00
(Increase) Decrease in Inventories 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 3.03M -1.21M -1.83M -12.23M
(Decrease) Increase In Other Current Liabilities 552.00K 1.27M -3.96M -4.40M
(Increase) Decrease In Other Working Capital -2.56M 0.00 0.00 0.00
Other Non-Cash Items 3.54M 3.17M 3.15M 960.00K
Net Cash From Continuing Operations -30.91M -25.60M -31.91M -73.64M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -30.91M -25.60M -31.91M -73.64M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 5.33M 7.09M
Purchases of Property, Plant & Equipment -80.00K 0.00 -15.00K -207.00K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 -10.67M
Other Cash from Investing Activities 0.00 10.00M -10.00M 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -80.00K 10.00M -4.69M -3.78M
Issuance of Debt 0.00 0.00 19.80M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 75.30M 10.39M 45.78M 35.76M
Repayment of Long-Term Debt 0.00 -18.09M -22.44M -4.47M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 0.00 0.00 -32.00K -37.00K
Net Cash From Financing Activities 75.30M -7.71M 43.12M 31.26M
Effect of Exchange Rate Changes 0.00 0.00 -1.00K -31.00K
Net Change in Cash & Cash Equivalents 44.31M -23.31M 6.51M -46.19M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ANTH Anthera Pharmaceuticals Inc

Chart of ANTH

Analysts Ratings for ANTH

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 3 2 3
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

ANTH Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs